Lars Wallentin

4.2k total citations
47 papers, 2.2k citations indexed

About

Lars Wallentin is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Epidemiology. According to data from OpenAlex, Lars Wallentin has authored 47 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Cardiology and Cardiovascular Medicine, 13 papers in Internal Medicine and 7 papers in Epidemiology. Recurrent topics in Lars Wallentin's work include Atrial Fibrillation Management and Outcomes (23 papers), Venous Thromboembolism Diagnosis and Management (13 papers) and Acute Myocardial Infarction Research (9 papers). Lars Wallentin is often cited by papers focused on Atrial Fibrillation Management and Outcomes (23 papers), Venous Thromboembolism Diagnosis and Management (13 papers) and Acute Myocardial Infarction Research (9 papers). Lars Wallentin collaborates with scholars based in Sweden, United States and Canada. Lars Wallentin's co-authors include Jonas Oldgren, Salim Yusuf, Stuart J. Connolly, Michael D. Ezekowitz, Paul Reilly, Agneta Siegbahn, Ziad Hijazi, C. B. Granger, Amit Parekh and John H. Alexander and has published in prestigious journals such as Circulation, Blood and Journal of the American College of Cardiology.

In The Last Decade

Lars Wallentin

45 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Wallentin Sweden	20	1.8k	619	252	209	208	47	2.2k
Michael Hanna United States	20	2.0k 1.1×	773 1.2×	293 1.2×	160 0.8×	141 0.7×	44	2.2k
Piera Angelica Merlini Italy	27	1.7k 0.9×	368 0.6×	187 0.7×	372 1.8×	56 0.3×	76	2.6k
Murat Çaylı Türkiye	19	800 0.4×	145 0.2×	188 0.7×	283 1.4×	41 0.2×	134	1.4k
Laila Stærk Denmark	23	2.2k 1.2×	565 0.9×	255 1.0×	168 0.8×	21 0.1×	44	2.5k
Christine S. Zuern Germany	22	1.4k 0.8×	171 0.3×	433 1.7×	97 0.5×	48 0.2×	75	1.7k
David Singh United States	6	3.0k 1.7×	366 0.6×	286 1.1×	248 1.2×	16 0.1×	35	3.3k
Juan Quiles Spain	21	1.0k 0.6×	109 0.2×	172 0.7×	359 1.7×	38 0.2×	69	1.5k
Frederic Kontny Norway	17	1.6k 0.9×	330 0.5×	65 0.3×	421 2.0×	49 0.2×	49	1.9k
Rasmus Havmoeller United States	4	3.0k 1.7×	365 0.6×	291 1.2×	251 1.2×	16 0.1×	4	3.3k
Mattía Galli Italy	22	1.4k 0.8×	296 0.5×	74 0.3×	240 1.1×	28 0.1×	138	1.9k

Countries citing papers authored by Lars Wallentin

Since Specialization

Citations

This map shows the geographic impact of Lars Wallentin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Wallentin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Wallentin more than expected).

Fields of papers citing papers by Lars Wallentin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Wallentin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Wallentin. The network helps show where Lars Wallentin may publish in the future.

Co-authorship network of co-authors of Lars Wallentin

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Wallentin. A scholar is included among the top collaborators of Lars Wallentin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Wallentin. Lars Wallentin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Giugliano, Robert P., André Zimerman, Jonathan Afilalo, et al.. (2025). Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin. Journal of the American College of Cardiology. 86(6). 426–439. 3 indexed citations

Haller, Paul M., Petr Jarolı́m, Andrea Bellavia, et al.. (2024). Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 84(16). 1528–1540. 7 indexed citations

Hijazi, Ziad, Agneta Siegbahn, Ulrika Andersson, et al.. (2020). Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials. Journal of Thrombosis and Haemostasis. 18(9). 2287–2295. 16 indexed citations

Andersen, Thomas T., Lars Wallentin, Axel Åkerblom, et al.. (2019). CXC MOTIF LIGAND 16: A NOVEL, INDEPENDENT PREDICTOR OF CARDIOVASCULAR DEATH AND MORBIDITY IN ACUTE CORONARY SYNDROMES - A SUBSTUDY OF THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL. Journal of the American College of Cardiology. 73(9). 71–71. 1 indexed citations

Douketis, J., Martina Brueckmann, Mandy Fraessdorf, et al.. (2015). Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure. Journal of Thrombosis and Haemostasis. 13. 393–394. 1 indexed citations

Held, Claes, Harvey D. White, Ralph Stewart, et al.. (2015). Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial. European Heart Journal. 36. 1104–1104.

Christersson, Christina, Lars Wallentin, Ulrika Andersson, et al.. (2014). D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial. Journal of Thrombosis and Haemostasis. 12(9). 1401–1412. 80 indexed citations

Husted, Steen, Stefan James, Richard G. Bach, et al.. (2014). The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal. 35(23). 1541–1550. 58 indexed citations

Tricoci, Pierluigi, Edmond Chen, Megan L. Neely, et al.. (2013). CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial. Circulation. 128(22). 2 indexed citations

10.

Hijazi, Ziad, Jonas Oldgren, Agneta Siegbahn, C. B. Granger, & Lars Wallentin. (2013). Biomarkers in atrial fibrillation: a clinical review. European Heart Journal. 34(20). 1475–1480. 215 indexed citations

11.

Husted, Steen, Lars Wallentin, Felicita Andreotti, et al.. (2013). General mechanisms of coagulation and targets of anticoagulants (Section I). Thrombosis and Haemostasis. 109(4). 569–579. 140 indexed citations

12.

Goodman, Shaun G., Robert M. Clare, Karen S. Pieper, et al.. (2010). Abstract 12092: Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO. Circulation. 122. 3 indexed citations

13.

Eikelboom, John W., Lars Wallentin, Salim Yusuf, et al.. (2010). Does dabigatran improve stroke‐prevention in atrial fibrillation? Reply to a rebuttal. Journal of Thrombosis and Haemostasis. 8(6). 1438–1439. 2 indexed citations

14.

Lind, Lars, Lars Wallentin, Tibor Kempf, et al.. (2009). Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. European Heart Journal. 30(19). 2346–2353. 197 indexed citations

15.

Peters, Ron J.G., Jean‐Pierre Bassand, R. Afzal, et al.. (2008). The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. European Heart Journal. 29(3). 324–331. 41 indexed citations

16.

Englund, Anders, et al.. (2007). Influence of left bundle branch block on long-term mortality in a population with heart failure. European Heart Journal. 28(20). 2449–2455. 61 indexed citations

17.

Westerhout, Cynthia M., Michael S. Lauer, Stefan James, et al.. (2007). Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women. European Heart Journal. 28(17). 2064–2069. 19 indexed citations

18.

Lindahl, Bertil, et al.. (2004). 884-2 Cardiac dysfunction in non-ST elevation ACS is partly reversible: Analysis of serial measurements of NT-Pro B-type natriutetic peptide. Journal of the American College of Cardiology. 43(5). A306–A306.

19.

Wallentin, Lars, et al.. (2001). The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS study. Clinical Cardiology. 24(S1). 12–14. 24 indexed citations

20.

Abrahamsson, Putte, et al.. (2001). Early assessment of long-term risk with continuous ST-segment monitoring among patients with unstable coronary syndromes. Results from 1-year follow-up in the TRIM study. Journal of Electrocardiology. 34(2). 103–108. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact